CoImmune Inc. is a US company based in Durham North Carolina that was founded in 2019 based on its expertise in the development and manufacture of cell-based therapeutics to treat unmet medical needs including cancer, autoimmune and inflammatory diseases. CoImmune has a 20,000 sq. ft. cGMP manufacturing facility capable of supporting clinical studies from Phase I through Phase 3. The company is preparing to initiate its first Phase 2 clinical trial using a strategic combination of immune-oncology therapeutics. In addition to developing its own therapeutic pipeline, the company plans to use its expertise and excess cGMP manufacturing capacity to provide revenue-generating contract services for cGMP consulting and the manufacturing of third-party clinical stage cell-based products.